|
Clinical variables
|
TopIIα expression (%)
|
P
|
Ki67 expression (%)
|
P
|
|---|
| |
High
|
Low
| |
High
|
Low
| |
|---|
|
Sex
| | | | | | |
|
Male
|
25 (22.5)
|
86 (77.5)
|
0.998
|
39 (35.1)
|
72 (64.9)
|
0.584
|
|
Female
|
9 (22.5)
|
31 (77.5)
| |
16 (40.0)
|
24 (60.0)
| |
|
Smoking status
| | | | | | |
|
No
|
16 (24.6)
|
49 (75.4)
|
0.591
|
25 (38.5)
|
40 (61.5)
|
0.651
|
|
Yes
|
18 (20.9)
|
68 (79.1)
| |
30 (34.9)
|
56 (65.1)
| |
|
Histology
| | | | | | |
|
Adenocarcinoma
|
14 (23.7)
|
45 (76.3)
|
0.775
|
22 (37.3)
|
37 (62.7)
|
0.860
|
|
Non- adenocarcinoma
|
20 (21.7)
|
72 (78.3)
| |
33 (35.9)
|
59 (64.1)
| |
|
Stage
| | | | | | |
|
I
|
10 (18.5)
|
44 (81.5)
|
0.177
|
13 (24.1)
|
41 (75.9)
|
0.034*
|
|
II
|
15 (31.9)
|
32 (68.1)
| |
23 (48.9)
|
24 (51.1)
| |
|
III
|
9 (18.0)
|
41 (82.0)
| |
19 (38.0)
|
31 (62.0)
| |
|
T stage
| | | | | | |
|
T1
|
13 (34.2)
|
25 (65.8)
|
0.148
|
18 (47.4)
|
20 (52.6)
|
0.168
|
|
T2
|
18 (18.2)
|
81 (81.8)
| |
34 (34.3)
|
65 (65.7)
| |
|
T3-4
|
3 (21.4)
|
11 (78.6)
| |
3 (21.4)
|
11 (78.6)
| |
|
N stage
| | | | | | |
|
N0
|
12 (19.4)
|
50 (80.6)
|
0.137
|
16 (25.8)
|
46 (74.2)
|
0.065
|
|
N1
|
16 (32.0)
|
34 (68.0)
| |
23 (46.0)
|
27 (54.0)
| |
|
N2
|
6 (15.4)
|
33 (84.6)
| |
16 (41.0)
|
23 (59.0)
| |
- * P < 0.05 was considered statistically significant
